Sodium-glucose co-transporter-2 inhibitors, cardiovascular outcomes and the impact of gender: Class effect or statistical play of chance?
作者信息
Patoulias Dimitrios, Papadopoulos Christodoulos, Doumas Michael
机构信息
Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, General Hospital "Hippokration", Thessaloniki, Greece.
Third Department of Cardiology, Aristotle University of Thessaloniki, General Hospital "Hippokration", Thessaloniki, Greece.
出版信息
Diabetes Metab Syndr. 2020 Jul-Aug;14(4):347. doi: 10.1016/j.dsx.2020.04.010. Epub 2020 Apr 11.
PMID:32305776
Abstract
摘要
相似文献
1
Sodium-glucose co-transporter-2 inhibitors, cardiovascular outcomes and the impact of gender: Class effect or statistical play of chance?钠-葡萄糖协同转运蛋白2抑制剂、心血管结局及性别影响：类效应还是统计学上的偶然？
Diabetes Metab Syndr. 2020 Jul-Aug;14(4):347. doi: 10.1016/j.dsx.2020.04.010. Epub 2020 Apr 11.
2
Sodium-glucose co-transporter-2 inhibitor and glucagon-like peptide-1 receptor agonist combination treatment: Promising, but shall we look at other indices?钠-葡萄糖协同转运蛋白2抑制剂与胰高血糖素样肽-1受体激动剂联合治疗：前景可期，但我们是否应关注其他指标？
Int J Cardiol. 2021 Jan 15;323:259. doi: 10.1016/j.ijcard.2020.08.049. Epub 2020 Aug 15.
3
The role of cost-effectiveness in the use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists.成本效益在钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂使用中的作用
Eur J Prev Cardiol. 2023 Jun 1;30(8):656-657. doi: 10.1093/eurjpc/zwad032.
4
Sodium-glucose co-transporter-2 inhibitors: know the patient and the drugs.钠-葡萄糖协同转运蛋白2抑制剂：了解患者与药物。
Hong Kong Med J. 2019 Aug;25(4):268-270. doi: 10.12809/hkmj195089.
5
Is there any place for sodium-glucose co-transporter-2 inhibitors in post-liver transplantation patients?
Dig Liver Dis. 2020 Feb;52(2):239-240. doi: 10.1016/j.dld.2019.10.016. Epub 2019 Nov 29.
6
Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.基于随机对照试验的系统评价和荟萃分析：相较于单独使用钠-葡萄糖共转运蛋白 2 抑制剂，胰高血糖素样肽-1 受体激动剂联合钠-葡萄糖共转运蛋白 2 抑制剂在血糖疗效和安全性方面的表现。
Diabetes Res Clin Pract. 2019 Dec;158:107927. doi: 10.1016/j.diabres.2019.107927. Epub 2019 Nov 13.
7
Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease.糖尿病合并心血管疾病患者中 SGLT2-i 与 GLP1-RA 的合理选择策略。
Curr Cardiol Rep. 2019 Jul 27;21(9):100. doi: 10.1007/s11886-019-1197-6.
8
First experience with sodium-glucose co-transporter 2 inhibitors in Polish patients with cardiovascular diseases.波兰心血管疾病患者使用钠-葡萄糖协同转运蛋白2抑制剂的首次经验。
Cardiol J. 2020;27(5):639-641. doi: 10.5603/CJ.a2020.0100. Epub 2020 Aug 13.
9
Meta-analysis Evaluating the Effect of Sodium-Glucose Co-Transporter-2 Inhibitors on the Risk for New-Onset Obstructive Sleep Apnea in Patients With Type 2 Diabetes Mellitus Regardless of Cardiovascular Disease at Baseline.评估钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病患者新发阻塞性睡眠呼吸暂停风险的影响的荟萃分析，无论基线时是否患有心血管疾病。
Am J Cardiol. 2022 Sep 15;179:116-117. doi: 10.1016/j.amjcard.2022.06.022. Epub 2022 Jul 20.
10
Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns.胰高血糖素样肽-1 受体激动剂与心血管事件：类别效应与个体模式。
Trends Endocrinol Metab. 2018 Apr;29(4):238-248. doi: 10.1016/j.tem.2018.01.011. Epub 2018 Feb 17.
引用本文的文献
1
Surrogate cardiovascular outcomes with sodium-glucose co-transporter-2 inhibitors in women: An updated meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂在女性患者中的替代心血管结局：一项更新的荟萃分析。
Indian Heart J. 2021 Jan-Feb;73(1):132-134. doi: 10.1016/j.ihj.2020.12.012. Epub 2020 Dec 25.
Zotero 插件